Mediwound Ltd Ord Sh (MDWD)

$15.16 +0.34 (2.29%)
Market Cap 194.84M
Revenue (ttm) 16.96M
Net Income (ttm) -23.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.80%
Debt to Equity Ratio 0.02
Volume 52,600
Avg Vol 88,892
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 85%
Beta 0.14
Analysts Strong Sell
Price Target $30.17

Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic ther...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 797 14100
Address:
42 Hayarkon Street, Yavne, Israel
Latest News on MDWD
MediWound price target lowered to $22 from $25 at Alliance Global

2026-05-28T21:35:50.000Z - 5 weeks ago

MediWound price target lowered to $22 from $25 at Alliance Global

MediWound price target lowered to $32 from $33 at Oppenheimer

2026-05-28T15:33:26.000Z - 5 weeks ago

MediWound price target lowered to $32 from $33 at Oppenheimer

MediWound Earnings Call Transcript: Q1 2026

May 27, 2026, 8:30 AM EDT - 5 weeks ago

MediWound Earnings Call Transcript: Q1 2026

MediWound Earnings release: Q1 2026

May 27, 2026, 8:30 AM EDT - 5 weeks ago

MediWound Earnings release: Q1 2026

MediWound reports Q1 EPS (23c), consensus (66c)

2026-05-27T11:14:53.000Z - 5 weeks ago

MediWound reports Q1 EPS (23c), consensus (66c)

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 27, 2026, 7:00 AM EDT - 5 weeks ago

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

MDLN

MediWound Slides: Corporate presentation

May 26, 2026, 7:00 AM EDT - 5 weeks ago

MediWound Slides: Corporate presentation

MediWound to Report First Quarter 2026 Financial Results

May 7, 2026, 8:00 AM EDT - 2 months ago

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

Apr 13, 2026, 7:30 AM EDT - 2 months ago

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Apr 7, 2026, 7:00 AM EDT - 3 months ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound says Vericel awarded ten-year contract valued at up to $197M

2026-04-02T19:37:47.000Z - 3 months ago

MediWound says Vericel awarded ten-year contract valued at up to $197M

VCEL

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Apr 2, 2026, 3:26 PM EDT - 3 months ago

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound management to meet with Maxim

2026-03-12T16:05:24.000Z - 4 months ago

MediWound management to meet with Maxim

MediWound Files Annual Report on Form 20-F

Mar 5, 2026, 4:30 PM EST - 4 months ago

MediWound Files Annual Report on Form 20-F

MediWound Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

MediWound Earnings Call Transcript: Q4 2025

MediWound Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

MediWound Annual report: Q4 2025

MediWound Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

MediWound Earnings release: Q4 2025

MediWound reports Q4 EPS (56c), consensus (61c)

2026-03-05T12:15:32.000Z - 4 months ago

MediWound reports Q4 EPS (56c), consensus (61c)

MediWound sees FY26 revenue $24M-$26M, consensus $26.21M

2026-03-05T12:14:40.000Z - 4 months ago

MediWound sees FY26 revenue $24M-$26M, consensus $26.21M

MediWound sees FY27 revenue $32M-$35M, sees FY28 revenue $50M-$55M

2026-03-05T12:14:25.000Z - 4 months ago

MediWound sees FY27 revenue $32M-$35M, sees FY28 revenue $50M-$55M

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 7:00 AM EST - 4 months ago

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound management to meet with Maxim

2026-03-03T15:01:53.000Z - 4 months ago

MediWound management to meet with Maxim

MediWound Slides: Corporate presentation

Mar 3, 2026, 7:00 AM EST - 4 months ago

MediWound Slides: Corporate presentation

MediWound Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 4 months ago

MediWound Transcript: TD Cowen 46th Annual Health Care Conference

MediWound Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:40 AM EST - 4 months ago

MediWound Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 19, 2026, 8:00 AM EST - 4 months ago

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

MediWound to Present at Upcoming Investor Conferences

Feb 17, 2026, 8:00 AM EST - 4 months ago

MediWound to Present at Upcoming Investor Conferences

MediWound sees FY25 revenue $17M, consensus $22.98M

2026-01-12T12:06:19.000Z - 6 months ago

MediWound sees FY25 revenue $17M, consensus $22.98M

MediWound sees FY26 revenue $24-26M, consensus $28.8M

2026-01-12T12:05:27.000Z - 6 months ago

MediWound sees FY26 revenue $24-26M, consensus $28.8M

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

MediWound reports clinical data on NexoBrid’s effectiveness

2025-12-10T12:10:37.000Z - 7 months ago

MediWound reports clinical data on NexoBrid’s effectiveness

MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Dec 10, 2025, 7:00 AM EST - 7 months ago

MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

MediWound price target raised to $36 from $31 at H.C. Wainwright

2025-11-21T11:10:36.000Z - 8 months ago

MediWound price target raised to $36 from $31 at H.C. Wainwright

MediWound Earnings Call Transcript: Q3 2025

Nov 20, 2025, 8:30 AM EST - 8 months ago

MediWound Earnings Call Transcript: Q3 2025

MediWound Earnings release: Q3 2025

Nov 20, 2025, 8:30 AM EST - 8 months ago

MediWound Earnings release: Q3 2025

MediWound reports Q3 EPS (24c), consensus (98c)

2025-11-20T12:06:10.000Z - 8 months ago

MediWound reports Q3 EPS (24c), consensus (98c)

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 7:00 AM EST - 8 months ago

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

MediWound Slides: Corporate Presentation

Nov 20, 2025, 7:00 AM EST - 8 months ago

MediWound Slides: Corporate Presentation

MediWound to Report Third Quarter 2025 Financial Results

Nov 5, 2025, 7:30 AM EST - 8 months ago

MediWound to Report Third Quarter 2025 Financial Results

MediWound completes commissioning of expanded GMP manufacturing facility

2025-11-03T13:20:37.000Z - 8 months ago

MediWound completes commissioning of expanded GMP manufacturing facility

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

Nov 3, 2025, 8:00 AM EST - 8 months ago

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®

MediWound announces $30M registered direct offering

2025-09-29T12:45:46.000Z - 9 months ago

MediWound announces $30M registered direct offering

MediWound down 8% at $16.50 following offering

2025-09-29T12:45:35.000Z - 9 months ago

MediWound down 8% at $16.50 following offering

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

Sep 29, 2025, 8:37 AM EDT - 9 months ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

MediWound announces marketing approval of NexoBrid in Australia

2025-09-25T11:40:37.000Z - 10 months ago

MediWound announces marketing approval of NexoBrid in Australia

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

Sep 25, 2025, 7:30 AM EDT - 10 months ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

MediWound Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 10 months ago

MediWound Transcript: H.C. Wainwright 27th Annual Global Investment Conference

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

Sep 2, 2025, 7:30 AM EDT - 10 months ago

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 7:30 AM EDT - 11 months ago

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediWound Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

MediWound Earnings Call Transcript: Q2 2025

MediWound Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

MediWound Earnings release: Q2 2025

MediWound reports Q2 EPS ($1.23), consensus (57c)

2025-08-14T11:11:06.000Z - 11 months ago

MediWound reports Q2 EPS ($1.23), consensus (57c)

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 11 months ago

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MediWound announces EscharEx Phase II data

2025-08-13T12:56:02.000Z - 11 months ago

MediWound announces EscharEx Phase II data

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

Aug 13, 2025, 8:45 AM EDT - 11 months ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 7:30 AM EDT - 11 months ago

MediWound to Report Second Quarter 2025 Financial Results

MediWound Earnings Call Transcript: Q1 2025

May 21, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings Call Transcript: Q1 2025

MediWound Earnings release: Q1 2025

May 21, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings release: Q1 2025

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025, 7:00 AM EDT - 1 year ago

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025, 7:30 AM EDT - 1 year ago

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

MediWound to Report First Quarter 2025 Financial Results

MediWound Earnings Call Transcript: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings Call Transcript: Q4 2024

MediWound Annual report: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

MediWound Annual report: Q4 2024

MediWound Earnings release: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

MediWound Earnings release: Q4 2024

MediWound Registration statement: Registration Filing

Mar 19, 2025, 8:00 AM EDT - 1 year ago

MediWound Registration statement: Registration Filing

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 7:00 AM EDT - 1 year ago

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

MediWound Transcript: TD Cowen 45th Annual Healthcare Conference

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Feb 25, 2025, 8:00 AM EST - 1 year ago

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound to launch Phase III trial for venous leg ulcers

Feb 12, 2025, 8:12 AM EST - 1 year ago

MediWound to launch Phase III trial for venous leg ulcers

MediWound Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 8:00 AM EST - 1 year ago

MediWound Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Feb 12, 2025, 7:00 AM EST - 1 year ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound Earnings Call Transcript: Q3 2024

Nov 26, 2024, 8:30 AM EST - 1 year ago

MediWound Earnings Call Transcript: Q3 2024

MediWound Earnings release: Q3 2024

Nov 26, 2024, 8:30 AM EST - 1 year ago

MediWound Earnings release: Q3 2024

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 26, 2024, 7:00 AM EST - 1 year ago

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Oct 10, 2024, 7:00 AM EDT - 1 year ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 3:30 PM EDT - 1 year ago

MediWound Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

MediWound Registration statement: Registration Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

MediWound Registration statement: Registration Filing

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Aug 15, 2024, 4:15 PM EDT - 2 years ago

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

MediWound Earnings Call Transcript: Q2 2024

MediWound Earnings release: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

MediWound Earnings release: Q2 2024

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 14, 2024, 7:00 AM EDT - 2 years ago

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Aug 5, 2024, 7:30 AM EDT - 2 years ago

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

MediWound to Report Second Quarter 2024 Financial Results

Aug 2, 2024, 8:00 AM EDT - 2 years ago

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Jul 29, 2024, 8:00 AM EDT - 2 years ago

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Jul 16, 2024, 7:30 AM EDT - 2 years ago

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Jul 15, 2024, 7:32 AM EDT - 2 years ago

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

MediWound Announces $25 Million Strategic Private Placement Financing

Jul 15, 2024, 7:00 AM EDT - 2 years ago

MediWound Announces $25 Million Strategic Private Placement Financing

MediWound Earnings Call Transcript: Q1 2024

Jun 3, 2024, 10:34 AM EDT - 2 years ago

MediWound Earnings Call Transcript: Q1 2024

MediWound Earnings release: Q1 2024

Jun 3, 2024, 10:34 AM EDT - 2 years ago

MediWound Earnings release: Q1 2024

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024, 7:00 AM EDT - 2 years ago

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024, 8:00 AM EDT - 2 years ago

MediWound to Report First Quarter 2024 Financial Results

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Apr 25, 2024, 8:00 AM EDT - 2 years ago

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

MediWound Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MediWound Earnings Call Transcript: Q4 2023

MediWound Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MediWound Annual report: Q4 2023

MediWound Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MediWound Earnings release: Q4 2023

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 8:00 AM EDT - 2 years ago

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Feb 12, 2024, 7:00 AM EST - 2 years ago

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

MediWound to Participate in Two Upcoming Investor Conferences

Feb 5, 2024, 8:00 AM EST - 2 years ago

MediWound to Participate in Two Upcoming Investor Conferences

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Jan 9, 2024, 7:00 AM EST - 2 years ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Dec 28, 2023, 7:00 AM EST - 2 years ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Dec 21, 2023, 8:00 AM EST - 2 years ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads